InflaRx N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IFRX research report →
Range $2 – $9
Price Chart
About the company
InflaRx N. V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States.
- CEO
- Niels C. Riedemann
- IPO
- 2017
- Employees
- 65
- HQ
- Jena, TH, DE
Get TickerSpark's AI analysis on IFRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $153.26M
- P/E
- -2.92
- PEG
- -0.05
- P/S
- -4117.87
- P/B
- 0.97
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
- Gross Margin
- 14418.50%
- Op Margin
- 96251.80%
- Net Margin
- 86420.93%
- ROE
- -31.81%
- ROIC
- -22.53%
Latest fiscal year · YoY change
- Revenue
- $29.33K-82.3%
- Gross Profit
- $-7,238,287-129.7%
- Op Income
- $-48,256,974
- Net Income
- $-45,633,780+0.9%
- EPS
- $-0.66+15.4%
- OCF Growth
- +30.1%
- FCF Growth
- +30.0%
- 52W High
- $2.95
- 52W Low
- $0.80
- 50D MA
- $1.59
- 200D MA
- $1.66
- Beta
- 2.40
- RSI (14)
- 27
- Avg Volume
- 868.66K
No earnings-call transcripts are available for IFRX yet.
- Free Float
- 85.2%
- Shares Outstanding
- 147.37M
- Float Shares
- 125.63M
of shares held by institutions
67 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Montanova Capital, LLC | 22.93M | 0 |
| Tcg Crossover Management, LLC | 14.50M | 0 |
| Fmr LLC | 9.31M | ▲ 1.14M |
| Commodore Capital LP | 9.27M | ▲ 1.97M |
| Spruce Street Capital LP | 6.09M | ▲ 733.97K |
| 683 Capital Management, LLC | 4.69M | ▼ 375.00K |
| Farallon Capital Management, L.L.C. | 3.31M | ▼ 15.00K |
| Ameriprise Financial Inc | 3.09M | ▲ 520.66K |
| Great Point Partners LLC | 3.05M | 0 |
| Adar1 Capital Management, LLC | 3.00M | 0 |
| Kalehua Capital Management LLC | 2.92M | ▲ 23.33K |
| Nantahala Capital Management, LLC | 2.69M | ▲ 2.69M |
Held by 14 ETFs
Biggest fund positions in IFRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Hellstrom Hege | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IFRX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on IFRX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now
zacks.com · Nov 13
Down 20.3% in 4 Weeks, Here's Why You Should You Buy the Dip in InflaRx (IFRX)
zacks.com · Nov 12
Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX)
defenseworld.net · Nov 8
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
globenewswire.com · Nov 6
InflaRx N.V. (IFRX) Analyst/Investor Day Transcript
seekingalpha.com · Nov 3
InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials
marketbeat.com · Nov 3
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
globenewswire.com · Nov 3
InflaRx Announces November Investor Events
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
